FDA Warns Chinese API Supplier for Deficient COAs, Quality

Drug Industry Daily
A A
The FDA issued a warning letter to an active pharmaceutical ingredient distributor in Chongqing southwestern China for serious problems with quality and certificates of analyses (COAs).

To View This Article:

Login

Subscribe To Drug Industry Daily